Company intelligence / Profile preview

ONCOtherapeutics

West Hollywood, California, United Statesoncotherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ONCOtherapeutics does not develop its own drugs but manages and oversees clinical trials for hematology and oncology therapies. It has supported studies evaluating agents such as ruxolitinib in multiple myeloma but does not sponsor these programs itself.

Therapeutic areas: HematologyOncology
Modalities: N/A
Industry: Contract Research Organization

Drug pipeline

1 asset

ruxolitinib + methylprednisolone

Phase 2

Indications: Relapsed/refractory multiple myeloma

Partnerships

No major pharmaceutical or biotech partnerships publicly listed; works with biopharma clients on contract basis.

Beyond the preview

Go deeper on ONCOtherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCOtherapeutics.

Explore the full profile